Purpose. To evaluate the effects of continuous local injection of risedronate in the prevention of bone resorption in a lengthened segment. Methods. 11 male rabbits underwent subperiosteal osteotomy of the left tibia and an external fixator was applied anteromedially. After a lag phase of one week, a 2-week distraction phase and a 5-week consolidation phase followed. Risedronate was continuously injected into the centre of the distracted segment at a rate of 10 µg/kg/day during the first 14 days of consolidation by a subcutaneously implanted osmotic pump. A control group received purified buffer solution (PBS) using the same protocol. The lengthened bone segments were evaluated using radiography, quantitative computed tomography, and 3-point bending mechanical test. Results. Risedronate injection prevented osteopenia as compared to PBS injection. The mean bone mineral content, volumetric density and cross-sectional area of the lengthened segments were significantly higher in the risedronate group than in controls (as much as 65%, 30%, and 25%, respectively). There was no significant difference between the 2 groups regarding the ultimate load to failure. Conclusion. Continuous local injection of risedronate into the lengthened segment can prevent osteopenia during distraction osteogenesis but fails to enhance mechanical strength of newly distracted segments.
INTRODUCTION
Distraction osteogenesis is a well-established method of bone lengthening in a wide range of clinical conditions, including congenital bone disorders, fracture non-unions, and neoplastic conditions. [1] [2] [3] Distraction osteogenesis is divided into 3 distinct phases, namely the lag phase, the distraction phase, and the consolidation phase. Of these, the 2 early phases are of relatively short duration and are not associated with substantial morbidity or complications. The consolidation phase, however, entails a prolonged period of immobilisation, which may result in serious complications. 3 In this regard, the faster the regenerate bone mature, the sooner the external fixator can be removed, and in theory a lower rate of complication should ensue.
In an attempt to accelerate new bone formation and maturation, various substances has been administered, including bone morphogenetic protein-2, 4 recombinant human fibroblast growth factor-2, 5 thrombin-related peptide, 6 and bisphosphonates. 7, 8 Bisphosphonates are the most effective and widely used anti-resorptive agents in the treatment of disease processes, whereby the number or activity of osteoclasts is increased. Recent animal studies revealed that mid-to-high systemic doses of nitrogen-containing bisphosphonates (N-BPs) effectively prevented bone resorption in newly formed bone segments, [9] [10] [11] [12] which suggests this approach may be suitable as an adjunct to distraction osteogenesis in clinical settings. Nonetheless, N-BPs should be used cautiously, as systemic use of bisphosphonates is associated with adverse reactions including jaw osteonecrosis, nephrocalcinosis, and inhibition of long bone growth. [13] [14] [15] To minimise such side effects, local use of low-dose bisphosphonates is suggested 16, 17 ; the drug reaches a relatively high local concentration, which prevents bone resorption more effectively than systemic administration. 16 Local injection of low-dose alendronate during distraction osteogenesis can prevent bone resorption, though it has no beneficial effect on the mechanical properties of the regenerate bone. 17 Moreover, direct infusion of low-dose alendronate into the lengthened segment during distraction osteogenesis prevents the osteopenia that begins early in the consolidation phase. 18 Risedronate is among the most potent bisphosphonates (5 to 10 fold that of alendronate), 19 but it may be associated with a higher rate of jaw osteonecrosis. 20 We evaluated the effects of risedronate on lengthened bone properties during distraction osteogenesis. We postulated that continuous local injection of low-dose risedronate into the lengthened bone segment can effectively prevent bone resorption of the lengthened segment in a rabbit model.
MATERIALS AND METHODS
This study was conducted from May 2008 to October 2008. The protocol of the experiment was approved by the local animal protection agency and the ethics committee of our hospitals. 11 white male New Zealand rabbits weighing 2±0.2 kg were anaesthetised. A unilateral external fixator was applied to the left tibia with 4 self-taping screws; a subperiosteal osteotomy was then performed between the second and third screw using a fine wire saw. 5 A small drill hole was made above the osteotomy and a 23-gauge needle was inserted obliquely into the marrow cavity until it reached the distal bone fragment. The needle was connected with a polyvinyl catheter embedded in the subcutaneous tissue until use.
After a lag phase of one week, distraction was started at a rate of 0.35 mm every 12 hours (0.7 mm/day). Distraction was continued for 2 weeks to achieve a lengthening of 10±0.1 mm. At the end of the distraction phase, an osmotic pump was subcutaneously implanted to the back of each animal. 5 The pump was connected to the polyvinyl catheter that had been embedded subcutaneously; the solution in the pump was gradually delivered into the centre of the lengthened segment for 14 days. 5 The animals were kept for another 5 weeks until consolidation of the lengthened segment (Fig. 1) .
The animals were randomly allocated to receive residronate (n=6) or purified buffer solution (PBS, n=5). Either risedronate (10 µg/kg/day) or PBS (30 µl/kg/day) was administered for 14 days from the Risedronate injection
Consolidation phase Distraction phase beginning of consolidation phase. The process of bone formation on the left tibiae was monitored every week using radiography. The operated limb was then exposed to 60 kV and 4 mA irradiation anteroposteriorly. The exposed digital luminescent cassettes were then processed by a digitiser.
The main outcome measures were quantitative assessment of regenerate bone mineral density and content (BMD and BMC) using quantitative computed tomography (pQCT). The rabbits were killed at postoperative week 8, and the tibiae prepared for pQCT studies. 18 slices were analysed in each left tibia; 6 slices each within the proximal, lengthened, and distal segments of the osteotomy site, with slice thickness of 1.67 mm. The same region of the right tibiae (non-operated side) were also analysed (only 6 slices were obtained) to evaluate the systemic effects of local risedronate delivery.
At the end of experiment, the mechanical properties of the tibiae were examined. The tibiae of both limbs were extracted and cleaned off soft tissues. Using a servo-hydraulic material testing system with a 1-kN load cell under displacement control (5 mm/ min), 3-point bending strength was measured until failure with a support span of 40 mm between the second and third pin holes. The ultimate load to failure was thus determined. 8 Numerical variables (pQCT and mechanical results) were analysed using independent sample Student's t tests. A p value of <0.05 were considered statistically significant.
RESULTS
In both groups, lengthening of 10±0.1 mm was successfully achieved and bone consolidation was obtained by the end of experiment (Fig. 2) . In the PBS group, the lengthened segments showed a characteristic zone structure consisting of a central radiolucent zone and 2 sclerotic zones. 21 After completion of distraction, the proximal and distal sclerotic zones became fused, shrunk and were eventually absorbed. By the end of experiment, the lengthened segments showed tubular bone structure with a new cortex.
On radiographs, bone formation was significantly enhanced in risedronate-infused tibiae. The periosteal callus dramatically expanded and the outer diameter of the lengthened segment was considerably increased. In PBS-infused tibiae, by the end of experiment the callus was gradually resorbed and replaced by thin cortical bone.
Based on the cross section of the lengthened tibia measured by pQCT at postoperative week 8, the risedronate-treated animals had advanced bony union and remodelling of the lengthened segment, and the cortical bone thickness was >1.5 fold thicker than in animals treated with PBS. These differences were especially obvious in the middle of lengthened bone segments (Fig. 3) . Three distinct areas of the lengthened tibia were analysed by pQCT. The proximal and distal segments contained the original tibia above and below the osteotomy, each 10 mm in length, respectively. The lengthened segments consisted of new bone regenerate. In the risedronate group, resorption of the bone in all 3 distinct areas was significantly less. The mean BMC and BMD of the lengthened segments in the risedronate group were 166% (p<0.001) and 130% (p<0.001) of those in the PBS group, respectively (Table) . The regenerate segments in the risedronate group showed significantly greater (p<0.001) bone circumference, total bone crosssectional area (CSA), cortical bone thickness, and cortical bone CSA (Table) . However, no significant difference between the groups was observed with regard to endosteal circumference and cancellus bone CSA (Table) .
In the non-operated limbs, the BMC was 15% greater in the risedronate than PBS group (p<0.001, Table) , as were the total CSA (12%) and periosteal circumference (6%). There were no significant differences between the 2 groups with regard to BMD or other indices related to cancellus bone properties (Table) . The mean ultimate load to failure, in the operated limb, showed a trend towards higher values in the risedronate-than PBS-treated animals (p=0.621, Table) . There was no significant difference with respect to the non-operated limbs, indicating no systemic effect of locally administered low-dose residronate (Table) .
DISCUSSION
Administration of anti-resorptive agents at the beginning of the consolidation phase yields better outcomes. 5 Low-dose injection to the distraction site diminishes the chance of systemic drug dispersion. Recent in vitro and in vivo studies are all in favour of low drug concentrations 17, [22] [23] [24] ; low-dose N-BPs are capable of inhibiting bone resorption (by osteoclasts) and stimulating osteoblasts, which in turn promotes new bone formation. Conversely, higher doses of N-BPs may result in osteoblast inhibition. [22] [23] [24] In an animal model of distraction osteogenesis, a low dose is more effective than a mid dose local use of alendronate in preserving the BMC of the lengthened segments; higher doses of alendronate could lead to inhibition of osteoblasts and therefore affect outcomes adversely. 17 In our study, low-dose continuous local injection of risedronate increased both BMC and BMD of the newly formed bone segments and prevented osteoporosis in the bone regions proximal and distal to the lengthened segments. The BMC of the lengthened segments was 65% higher in the risedronate group, as was in the segments proximal and distal to the regenerate bone (31% and 21%, respectively). In addition, in risedronate group the regenerate bone CSA and periosteal circumference were significantly greater (25% and 12.1%, respectively). These findings support the effectiveness of local administration of N-BPs and are in consistent with previous studies with the local use of N-BPs other than risedronate. 17, 25 Mechanical properties of the regenerate bone in distraction osteogenesis are of utmost importance for clinical practice. In our study, the ultimate mean load to failure in the lengthened bone of the residronate group was 77±26 N, as compared to 71±10 N in the PBS group (p=0.621). The lack of statistical significance may be due to the small number of animals in our study, and is in line with previous studies. 17, 25 In a rat model, a single shot of local pamidronate positively affected BMC of the callus, but failed to strengthen it. 25 Continues infusion of low-dose alendronate resulted in enhancement of ultimate strength of the rabbit tibia by approximately 2 fold. 18 In our study, the BMC (14.5%) and CSA (12.2%) in the same region of the non-operated leg were significantly greater in the risedronate group, suggestive of a systemic dispersion of the drug. Systemic effects for locally administered bisphosphonates have been reported, 25, 26 using radiolabelled alendronate in a rat model of mandibular implant placement. Only 10% of locally implanted alendronate-containing gel was absorbed by the surrounding bone, whereas the rest was dispersed in variable concentrations (i.e. from 0.2% in tibiae to 2% on the contralateral side of the mandible) elsewhere in the rats' bodies. 26 Local administration of a single dose of pamidronate, even in low concentrations result in systemic effects of the drug on the contralateral limb. 25 However, some authors reported no systemic effects after lowto-mid dose local administration of alendronate. 17 The discrepancies could be partly explained by differences in the methods for evaluation of systemic effects and the N-BP administration protocols used. The studies that reported systemic effects for locally applied N-BPs used a quantitative method. 25, 26 On the contrary, qualitative radiographic studies may lack sensitivity for detection of slight alterations induced by the extremely low concentrations of drug that reach contralateral-side bones. 17 To minimise the systemic dispersion of the drug, the basis for N-BP dispersion should be analysed. N-BP has a great affinity for exposed mineral which is most likely at the sites of osteoclast activity. 19 Continuous administration of drug can ensure continued inhibition of osteoclast function, but the exposed bone mineral may soon become saturated resulting in greater systemic dispersion of the drug. This problem may best be resolved by using lower concentrations over a longer period of the consolidation phase.
Although using continuous infusion pumps is routine in regional anaesthesia and pain management, their use during distraction osteogenesis for local injection of drugs to the zone of new formation has not yet been investigated in the human model. However, any benefit from their use would be difficult to achieve without an increased risk of infection.
CONCLUSION
Continuous local injection of risedronate into the lengthened segment during the consolidation phase appeared to prevent bone resorption. It increased BMC, BMD, bone CSA, and periosteal circumference of the lengthened segments as well as the proximal and distal segments. However, no significant beneficial mechanical effects were shown. Further studies using a larger number of animals in each group and the addition of groups with longer periods of lower-dose local injections of risedronate are suggested.
